Your browser doesn't support javascript.
loading
Antibiotic-induced acceleration of type 1 diabetes alters maturation of innate intestinal immunity.
Zhang, Xue-Song; Li, Jackie; Krautkramer, Kimberly A; Badri, Michelle; Battaglia, Thomas; Borbet, Timothy C; Koh, Hyunwook; Ng, Sandy; Sibley, Rachel A; Li, Yuanyuan; Pathmasiri, Wimal; Jindal, Shawn; Shields-Cutler, Robin R; Hillmann, Ben; Al-Ghalith, Gabriel A; Ruiz, Victoria E; Livanos, Alexandra; van 't Wout, Angélique B; Nagalingam, Nabeetha; Rogers, Arlin B; Sumner, Susan Jenkins; Knights, Dan; Denu, John M; Li, Huilin; Ruggles, Kelly V; Bonneau, Richard; Williamson, R Anthony; Rauch, Marcus; Blaser, Martin J.
Affiliation
  • Zhang XS; Department of Medicine, New York University Langone Medical Center, New York, United States.
  • Li J; Human Microbiome Program, New York University Langone Medical Center, New York, United States.
  • Krautkramer KA; Department of Medicine, New York University Langone Medical Center, New York, United States.
  • Badri M; Human Microbiome Program, New York University Langone Medical Center, New York, United States.
  • Battaglia T; Department of Biomolecular Chemistry, Wisconsin Institute for Discovery, University of Wisconsin School of Medicine and Public Health, Madison, United States.
  • Borbet TC; Department of Medicine, New York University Langone Medical Center, New York, United States.
  • Koh H; Human Microbiome Program, New York University Langone Medical Center, New York, United States.
  • Ng S; Center for Data Science, New York University, New York, United States.
  • Sibley RA; Department of Medicine, New York University Langone Medical Center, New York, United States.
  • Li Y; Human Microbiome Program, New York University Langone Medical Center, New York, United States.
  • Pathmasiri W; Department of Medicine, New York University Langone Medical Center, New York, United States.
  • Jindal S; Human Microbiome Program, New York University Langone Medical Center, New York, United States.
  • Shields-Cutler RR; Department of Population Health, New York University Langone Medical Center, New York, United States.
  • Hillmann B; Department of Medicine, New York University Langone Medical Center, New York, United States.
  • Al-Ghalith GA; Human Microbiome Program, New York University Langone Medical Center, New York, United States.
  • Ruiz VE; Department of Medicine, New York University Langone Medical Center, New York, United States.
  • Livanos A; Human Microbiome Program, New York University Langone Medical Center, New York, United States.
  • van 't Wout AB; Nutrition Research Institute, University of North Carolina at Chapel Hill School of Public Health, Kannapolis, United States.
  • Nagalingam N; Nutrition Research Institute, University of North Carolina at Chapel Hill School of Public Health, Kannapolis, United States.
  • Rogers AB; Department of Medicine, New York University Langone Medical Center, New York, United States.
  • Sumner SJ; Human Microbiome Program, New York University Langone Medical Center, New York, United States.
  • Knights D; Computer Science and Engineering, BioTechnology Institute, University of Minnesota, St. Paul, United States.
  • Denu JM; Computer Science and Engineering, BioTechnology Institute, University of Minnesota, St. Paul, United States.
  • Li H; Computer Science and Engineering, BioTechnology Institute, University of Minnesota, St. Paul, United States.
  • Ruggles KV; Department of Medicine, New York University Langone Medical Center, New York, United States.
  • Bonneau R; Human Microbiome Program, New York University Langone Medical Center, New York, United States.
  • Williamson RA; Department of Medicine, New York University Langone Medical Center, New York, United States.
  • Rauch M; Human Microbiome Program, New York University Langone Medical Center, New York, United States.
  • Blaser MJ; Janssen Prevention Center London, Janssen Pharmaceutical Companies of Johnson and Johnson, London, United Kingdom.
Elife ; 72018 07 25.
Article in En | MEDLINE | ID: mdl-30039798
ABSTRACT
The early-life intestinal microbiota plays a key role in shaping host immune system development. We found that a single early-life antibiotic course (1PAT) accelerated type 1 diabetes (T1D) development in male NOD mice. The single course had deep and persistent effects on the intestinal microbiome, leading to altered cecal, hepatic, and serum metabolites. The exposure elicited sex-specific effects on chromatin states in the ileum and liver and perturbed ileal gene expression, altering normal maturational patterns. The global signature changes included specific genes controlling both innate and adaptive immunity. Microbiome analysis revealed four taxa each that potentially protect against or accelerate T1D onset, that were linked in a network model to specific differences in ileal gene expression. This simplified animal model reveals multiple potential pathways to understand pathogenesis by which early-life gut microbiome perturbations alter a global suite of intestinal responses, contributing to the accelerated and enhanced T1D development.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Diabetes Mellitus, Type 1 / Gastrointestinal Microbiome / Immunity, Innate / Anti-Bacterial Agents Limits: Animals Language: En Journal: Elife Year: 2018 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Diabetes Mellitus, Type 1 / Gastrointestinal Microbiome / Immunity, Innate / Anti-Bacterial Agents Limits: Animals Language: En Journal: Elife Year: 2018 Document type: Article Affiliation country: